These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 33559791)
1. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop. Bie C; Chen Y; Tang H; Li Q; Zhong L; Peng X; Shi Y; Lin J; Lai J; Wu S; Tang S Dig Dis Sci; 2022 Feb; 67(2):569-584. PubMed ID: 33559791 [TBL] [Abstract][Full Text] [Related]
2. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression. Bie CQ; Liu XY; Cao MR; Huang QY; Tang HJ; Wang M; Cao GL; Yi TZ; Wu SL; Xu WJ; Tang SH Oncotarget; 2016 Nov; 7(48):79305-79318. PubMed ID: 27813495 [TBL] [Abstract][Full Text] [Related]
3. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076 [TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861 [TBL] [Abstract][Full Text] [Related]
6. miR-515-5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway. Ni JS; Zheng H; Ou YL; Tao YP; Wang ZG; Song LH; Yan HL; Zhou WP Surg Oncol; 2020 Sep; 34():113-120. PubMed ID: 32891315 [TBL] [Abstract][Full Text] [Related]
7. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994 [TBL] [Abstract][Full Text] [Related]
8. CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway. Zheng SS; Wu JF; Wu WX; Hu JW; Zhang D; Huang C; Zhang BH Hepatol Int; 2024 Oct; 18(5):1499-1515. PubMed ID: 38769286 [TBL] [Abstract][Full Text] [Related]
9. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway. Zhao Z; Song J; Tang B; Fang S; Zhang D; Zheng L; Wu F; Gao Y; Chen C; Hu X; Weng Q; Yang Y; Tu J; Ji J J Exp Clin Cancer Res; 2020 Nov; 39(1):259. PubMed ID: 33234142 [TBL] [Abstract][Full Text] [Related]
10. Circ_0072088 promotes progression of hepatocellular carcinoma by activating JAK2/STAT3 signaling pathway via miR-375. Li L; Xiao C; He K; Xiang G IUBMB Life; 2021 Sep; 73(9):1153-1165. PubMed ID: 34148288 [TBL] [Abstract][Full Text] [Related]
11. Yan Q; Jiang L; Liu M; Yu D; Zhang Y; Li Y; Fang S; Li Y; Zhu YH; Yuan YF; Guan XY Cancer Res; 2017 Nov; 77(21):5831-5845. PubMed ID: 28904065 [TBL] [Abstract][Full Text] [Related]
12. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Yang S; Luo C; Gu Q; Xu Q; Wang G; Sun H; Qian Z; Tan Y; Qin Y; Shen Y; Xu X; Chen SH; Chan CC; Wang H; Mao M; Fang DD Oncotarget; 2016 Feb; 7(5):5461-9. PubMed ID: 26701727 [TBL] [Abstract][Full Text] [Related]
13. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338 [TBL] [Abstract][Full Text] [Related]
14. CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a/JAK1/STAT3 signaling. Yang L; Xue H; Sun Y; Zhang L; Xue F; Ge R Cell Death Dis; 2020 Jul; 11(7):605. PubMed ID: 32732872 [TBL] [Abstract][Full Text] [Related]
15. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398 [TBL] [Abstract][Full Text] [Related]
16. miR-30e acts as a tumor suppressor in hepatocellular carcinoma partly via JAK1/STAT3 pathway. Mao J; Hu X; Pang P; Zhou B; Li D; Shan H Oncol Rep; 2017 Jul; 38(1):393-401. PubMed ID: 28560434 [TBL] [Abstract][Full Text] [Related]
17. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Liao J; Xu T; Zheng JX; Lin JM; Cai QY; Yu DB; Peng J Int J Mol Med; 2013 Jul; 32(1):79-84. PubMed ID: 23613111 [TBL] [Abstract][Full Text] [Related]
18. Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway. Tang W; Feng X; Zhang S; Ren Z; Liu Y; Yang B; lv B; Cai Y; Xia J; Ge N Cell Physiol Biochem; 2015; 36(3):1223-36. PubMed ID: 26138883 [TBL] [Abstract][Full Text] [Related]
19. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo. Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941 [TBL] [Abstract][Full Text] [Related]
20. The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor. Xu G; Chu J; Shi Y; Huang L; Fu J Growth Horm IGF Res; 2022 Oct; 66():101499. PubMed ID: 36084573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]